

Supplementary Materials for

Modelling suggests blood group incompatibility may substantially reduce SARS-CoV-2 transmission

Peter Ellis

Correspondence to: p.j.i.ellis@kent.ac.uk

This PDF file includes:

Materials and Methods
Supplementary Text
Fig. S1

Materials and Methods

An SIR model of ABO-interference with virus transmission

A standard SIR model of infection divides the population into three compartments, Susceptible, Infectious, Recovered, representing the proportion of individuals in the population with each status, and thus $S + I + R = 1$. These compartments are linked by three differential equations:

$$\frac{dS}{dt} = -\beta \cdot S \cdot I + \omega \cdot R$$

$$\frac{dI}{dt} = \beta \cdot S \cdot I - \nu \cdot I$$

$$\frac{dR}{dt} = \nu \cdot I - \omega \cdot R$$

The parameters β and ν represent the rate constants for infection and recovery, and their reciprocals $1 / \beta$ and $1 / \nu$ represent the average time required for one infectious individual to transmit to one susceptible individual, and the average duration of the infectious period. The product $\beta \cdot \nu$ represents the basic reproductive number R_0 . The parameter ω represents the rate constant for loss of immunity, and thus transfer from the R compartment back to S. Its reciprocal $1 / \omega$ represents the average duration of immunity following recovery.

Here, I extend this model by splitting each of S, I and R into four subcompartments representing the four ABO blood group phenotypes. These are then linked by a set of twelve equations:

$$\frac{dS_A}{dt} = -\beta \cdot S_A \cdot (I_A + \rho I_B + \rho I_{AB} + I_O) + \omega \cdot R_A$$

$$\frac{dS_B}{dt} = -\beta \cdot S_B \cdot (\rho I_A + I_B + \rho I_{AB} + I_O) + \omega \cdot R_B$$

$$\frac{dS_{AB}}{dt} = -\beta \cdot S_{AB} \cdot (I_A + I_B + I_{AB} + I_O) + \omega \cdot R_{AB}$$

$$\frac{dS_O}{dt} = -\beta \cdot S_O \cdot (\rho I_A + \rho I_B + \rho I_{AB} + I_O) + \omega \cdot R_O$$

$$\frac{dI_A}{dt} = \beta \cdot S_A \cdot (I_A + \rho I_B + \rho I_{AB} + I_O) - \nu \cdot I_A$$

$$\frac{dI_B}{dt} = \beta \cdot S_B \cdot (\rho I_A + I_B + \rho I_{AB} + I_O) - \nu \cdot I_B$$

$$\frac{dI_{AB}}{dt} = \beta \cdot S_{AB} \cdot (I_A + I_B + I_{AB} + I_O) - \nu \cdot I_{AB}$$

$$\frac{dI_O}{dt} = \beta \cdot S_O \cdot (\rho I_A + \rho I_B + \rho I_{AB} + I_O) - \nu \cdot I_O$$


$$\frac{dR_A}{dt} = \nu \cdot I_A - \omega \cdot R_A$$

$$\frac{dR_B}{dt} = \nu \cdot I_B - \omega \cdot R_B$$

$$\frac{dR_{AB}}{dt} = \nu \cdot I_{AB} - \omega \cdot R_{AB}$$

$$\frac{dR_O}{dt} = \nu \cdot I_O - \omega \cdot R_O$$

This can be graphically represented by the diagram on the right, with full arrows representing unimpeded transmission (infection rate = β) and dashed arrows representing impeded transmission (infection rate = $\rho \cdot \beta$).



These equations were implemented as a Microsoft Excel spreadsheet (available from [URL TO ADD](#)). In this model R_0 is not a well-defined quantity since even in a fully susceptible population the current effective R value, denoted $R(t)$, depends on ρ and on the blood type distributions in both S and I. In this paper, I use R_{\max} to indicate the product $\beta \cdot \nu$, i.e. the R_0 that would be observed in the absence of any ABO-interference. This is thus the maximal possible value of $R(t)$, and would be observed if $\rho = 100\%$, or if all infected individuals are type O. For

the work presented here, all epidemics were initiated by transferring 1/1,000,000 of the population from S to I at time $t=0$. This for example represents an initial importation of ~ 9 infected index cases into a city the size of London. Varying these boundary conditions from 1/10,000 to 1/100,000,000 has no effect other than accelerating or retarding the initial progress of the epidemic (not shown). Except where otherwise specified in the main text, all index cases were assumed to be of blood group O. For the main text, immunity was assumed to be permanent and thus $\omega = 0$. The case where $\omega = 0$ and immunity wanes over time is considered below.

Supplementary Text

The effect of waning immunity for a virus subject to ABO-interference

When immunity is allowed to wane over time, and the duration of immunity ($1 / \omega$) is substantially longer than the duration of infection ($1 / \nu$), then population spread of the virus can resume once the population level of immunity falls below the herd immunity threshold. Over time this leads to damped oscillatory behaviour, with recurrent pulses of infection converging on a final steady state. In this final steady state, by definition $R(t) = 1$, i.e. there is steady sustained transmission with levels neither growing nor shrinking. (**Figure S1**). The relative risk to non-O blood groups is less pronounced during this final steady state compared to the initial quasi-steady state during the early phase of pandemic spread, but remains non-zero. In the final steady state, with waning immunity and recurrent infection, the relative risk is best interpreted as a difference in the *frequency* of infection: e.g. if type A has a relative risk of 1.1 compared to type O, it means type A individuals are 10% more likely to suffer an infection within any given time period. The final population disease burden, i.e. the final value of I depends on the duration of immunity, with a shorter immune duration leading to a higher final prevalence.

Intriguingly, while the initial quasi-steady state is independent of R_{\max} (see main text for details), the final steady state does depend on R_{\max} . When R_{\max} is high, the final relative risk for all blood groups is close to unity. When R_{\max} is low, then the final relative risk for all blood groups is similar to that seen in the initial steady state. Intuitively, this follows from the fact that for a highly contagious disease with a high R_{\max} , everyone will become infected as soon as their immunity wears off, irrespective of blood type. For a less contagious disease with a low R_{\max} , then there is more scope for differential susceptibility to play a part in how frequently individuals become infected.

For seasonal coronaviruses, if these are subject to ABO-interference, this means similar results should be observed for these as for SARS-CoV-2. It would therefore be interesting to determine whether non-O blood groups are indeed more likely to suffer more frequent repeat coronavirus infections. More speculatively, given the emerging evidence that COVID-19 is a multisystemic infection with particular impact on clotting pathways [1], could it be possible that the endemic coronaviruses may also have some effect on the likelihood of thrombosis? This could potentially explain the widely-observed phenomenon that type O individuals are on average slightly less likely to suffer from thrombosis and clotting-related myocardial infarction. This has been hitherto ascribed to an effect of ABO blood group on von Willebrand factor levels, but the causal link between the two remains obscure [2].

Supplementary References

- 1) Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol*. 2020 Jun;7(6):e438-e440.
- 2) Franchini M, Lippi G. Relative Risks of Thrombosis and Bleeding in Different ABO Blood Groups. *Semin Thromb Hemost*. 2016 Mar;42(2):112-7.




Fig. S1.

These panels show the evolution of various modelled parameters for epidemics involving waning immunity. All epidemics were seeded at with type O index cases, and thus $R(t) = R_{\max}$ at time $t=0$. For all sub-panels, X axis denotes days. Y axes: (first column) proportion of the population infected; (second column) $R(t)$ as a fraction of R_{\max} ; (third column) distribution of blood types among currently infected individuals; (fourth column) cumulative risk of infection for each blood type relative to type O.

Rows **A-E** are initialised with the same typical Western population blood type distribution used in Figures 1 and 2 of the main manuscript. **A:** $R_{\max} = 4$, $\rho = 20\%$, $\omega = 1/90 \text{ days}^{-1}$. **B:** $R_{\max} = 4$, $\rho = 20\%$, $\omega = 1/180 \text{ days}^{-1}$. **C:** $R_{\max} = 4$, $\rho = 20\%$, $\omega = 1/360 \text{ days}^{-1}$. **D:** $R_{\max} = 2$, $\rho = 20\%$, $\omega = 1/90 \text{ days}^{-1}$. **E:** $R_{\max} = 40$, $\rho = 20\%$, $\omega = 1/90 \text{ days}^{-1}$.

Row **F:** $R_{\max} = 4$, $\rho = 20\%$, $\omega = 1/90 \text{ days}^{-1}$, initialised with an Indian population blood type distribution of 21.4%/39.9%/9.4%/29.3% type A/B/AB/O [17].

Row **G:** $R_{\max} = 4$, $\rho = 20\%$, $\omega = 1/90 \text{ days}^{-1}$, initialised with a Peruvian population blood type distribution of 18.9%/8.1%/1.6%/71.4% type A/B/AB/O [18].

The relative risks to different blood groups during the final steady state are independent of ω (compare **A,B,C**), but depend on R_{\max} (compare **B,D,E**) and on the background blood group distribution (compare **B,F,G**). The final case burden depends on all of R_{\max} , ω , ρ and the background blood group distribution.